Abstract
The spectrum of adverse reactions to blood product transfusion ranges from a benign clinical course to serious morbidity and mortality. There have been many advances in technologies and transfusion strategies to decrease the risk of adverse reactions. Our aim is to address a few of the advancements in increasing the safety of the blood supply, specifically pathogen reduction technologies, bacterial contamination risk reduction, and transfusion associated acute lung injury risk mitigation strategies.
Cite
CITATION STYLE
Rogers, T. S., Fung, M. K., & Harm, S. K. (2015). Recent Advances in Preventing Adverse Reactions to Transfusion. F1000Research. Faculty of 1000 Ltd. https://doi.org/10.12688/f1000research.7048.1
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.